cyrilzakka/clinical-trials huggingface dataset:
MWM Technique in Patients With Knee OA

The aim of this study is to investigate the effect of the MWM technique on pain, normal joint movement, proprioception and quality of life in patients with knee osteoarthritis (OA).

The aim of this study is to investigate the effect of the MWM technique on pain, normal joint movement, muscle strength, proprioception, mobility, balance, functionality and quality of life in patients with knee OA.

Eligibility Criteria:
Inclusion Criteria:

* being diagnosed with knee osteoarthritis,
* being diagnosed with knee OA at the earliest 6 months ago

Exclusion Criteria:

* Participants who were pregnant,
* had knee surgery, had an infection,
* had a pacemaker, had an infraction,
* had cancer, or were receiving corticosteroid treatment were excluded from the study
Wuhan High Myopia Study

The study aims to observe the long-term changes of ocular（especially fundus） structure and visual function in patients with high myopia, so as to provide evidence for the prevention, diagnosis and prognosis of high myopia.

High myopia is defined as a refractive error of ≤-6.00D or an axial length greater than 26mm. In recent years, the population of highly myopic individuals has been increasing rapidly. Scholars predict that if no effective interventions are taken, the global incidence rate of myopia is expected to increase from 22.9% in 2000 to 49.8% in 2050, and the visual impairment caused by high myopia will be seven times higher than in 2000 on a global scale. In China, a survey conducted by the National Health Commission in 2018 found that highly myopic students accounted for 21.9% of third-year high school students, indicating that high myopia has become a major public health issue due to its prevalence among younger populations.

In recent years, with the development of ocular imaging technologies such as optical coherence tomography (OCT) and corresponding image analysis techniques, high-resolution, non-invasive, fast and in vivo retinal imaging has become more accessible. This has led to the discovery and exploration of various imaging parameters related to optic disc and macula changes in highly myopic patients. We will conduct a 4 years prospective cohort study in the population of 1000 high myopia and controls which have established in mainly college student population, using the latest OCT-A and SS-OCT to observe the long-term changes of fundus structure combined with visual function in patients with high myopia , and explore biomarkers affecting visual function, so as to provide basis for prevention and control of high myopia and prognosis.

Eligibility Criteria:
Inclusion Criteria:

* Voluntarily sign informed consent;
* Commit to follow the research procedures and cooperate with the whole process of the study;
* Age ≥18 years old;
* Best corrected visual acuity ≥0.1;
* Spherical Equivalent Refraction≤-6.00D or axial length ≥26mm in high myopia group；

Exclusion Criteria:

* Unable or unwilling to sign informed consent;
* Unable to cooperate with the examination;
* Astigmatism ≤-1.5D；
* Patients with refractive interstitial opacity so that fundus images cannot be collected；
* Patients with fundus diseases such as diabetic retinopathy, hypertensive retinopathy, age-related macular degeneration, retinal vein obstruction, retinal artery obstruction, etc
A Drug Interaction Study of Cilnidipine and Valsartan

The investigators investigate the potential pharmacokinetic drug-drug interaction between Cilnidipine 10 mg and Valsartan 160 mg in healthy male volunteers who receive Cilnidipine 10 mg alone, Valsartan 160 mg , and both together in a 3 period repeatedly.

To evaluate the safety, drug-tolerance, pharmacokinetics of Cilnidipine 10 mg or Valsartan 160 mg monotherapy or Cilnidipine 10 mg and Valsartan 160 mg combination in healthy male subjects.

Eligibility Criteria:
Inclusion Criteria:

1. Healthy male volunteers, age 20 to 40 years
2. The result of Body Mass Index(BMI) is not less than 18.5 kg/m2 , no more than 25 kg/m2 and body weight are least 55 kg
3. Subjects who have no congenital or chronic disease and no abnormal symptom or opinion
4. Acceptable serum test, hematologic test, blood chemistry examination, urin test and ECG, physical examination during screening
5. Subjects who have ability to comprehend the objectives, contents of study and property of study drug before participating in trial and have willingness to sign of informed consent in writing

Exclusion Criteria:

1. A subject with clinical evidence or history of hepatic (including carrier of hepatitis virus), renal, respiratory, endocrine, neurologic, immunologic, hematologic, oncologic, psychiatric, or cardiovascular disease
2. A subject with a history of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
3. A subject with history of drug allergies (aspirin, antibiotics, including study drug etc.), or history of clinically significant allergies
4. Systolic blood pressure \<100mmHg or Diastolic blood pressure \< 60 mmHg, systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100mmHg(Sitting blood pressure) during the screening procedure.
5. Presence or history of drug abuse or positive result in urine drug screening test
6. Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 14 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (if used medication is considered acceptable by investigator, patients can be included)
7. Participation in clinical trials of any drug within 60 days prior to the participation of the study
8. Blood donation during 2 months or apheresis during 1 month before the study
9. Use of alcohol over 21 units/weeks
10. Smoker who smoke more than 20 cigarettes per day
11. A subject who takes grapefruit, grapefruit juice, or grapefruit-containing products within 3 days prior to the participation of the study
12. A subject who takes St John's wort or some food including the ingredient within 14 days prior to the participation of the study
13. Judged to be inappropriate for the study by the investigator after reviewing clinical laboratory results or other reasons.
Prevalence of Helicobacter Pylori Infection and Gastric Cancer in the West Indies

Estimating the prevalence of Helicobacter Pylori infection in newly diagnosed stomach cancers in the West-Indies will help to understand the epidemiology of this cancer, which is over-incident in the West Indies compared to France. In addition, the constitution of a biobank (tumor tissues, healthy tissues and serum) will allow to set up in a second time etiological studies to identify other risk factors in particular in connection with the exposure to environmental pollutants to adapt the prevention measures.

In the Antilles-Guyana, gastric cancer affects approximately 80 men and women each year in Guadeloupe and Martinique, and 20 in French Guiana. It is more frequent than in France and represents 4.5% of cancers in men in Martinique, 5.3% in Guadeloupe and 5.7% in French Guyana. It is the 3rd most common cancer site in men in Guadeloupe and Martinique, and the 4th in French Guiana. In women, it is the 3rd most frequent cancer in Martinique and the 4th in Guadeloupe, whereas it is less frequent in French Guiana.

Studies are needed to estimate this prevalence in the general population and in cancer patients. The prevalence of Helicobacter pylori infection is not well known in the general population in the Caribbean and when gastric cancer is diagnosed, the bacterium is rarely tested.

Dietary habits in our regions are characterized by a high consumption of salt (salted), meat and smoked fish. These dietary habits, common to some Southeast Asian countries, could partly explain the high incidence of stomach cancer observed. But environmental risk factors could also be involved.

Patients referred to gastroenterology with a suspected endoscopic diagnosis of gastric cancer will be offered to participate in the study after the fibroscopy has been performed and their consent will be obtained for the use of diagnostic specimen remains for research purposes.

Eligibility Criteria:
Inclusion Criteria:

1. Patient over 18 years of age, residing for at least 6 months in Martinique, with a primary diagnosis of gastric cancer
2. Patient having read the information note and having signed the consent to participate in the study
3. Patient with social security coverage

Exclusion Criteria:

1. Refusal to participate
2. Patient who could not answer the questionnaires
3. Patient not affiliated to a social security system
4. Patient not fluent in French
5. Patient under legal protection (legal protection, guardianship, curators, etc.)
Effect of Helicobacter Pylori on the Availability of Vitamin E and C

This study argues that H.pylori infection, by increasing the production of reactive oxygen species, increases the utilization of dietary antioxidants(Vit E and Vit C) that serve in quenching the free radicals, thus decreasing their serum levels and confounding their protective effect against gastric cancer.

It has been postulated that dietary antioxidants may reduce cancer risk by modulating red-ox status, by preventing biological oxidation, and by inhibiting the formation of carcinogen. However, supplementation studies and prospective studies have yielded contradictory results. In the case of gastric cancer, H.pylori infection, which is known to be associated with a higher risk of the disease, results in an increased production of ROS \& RNS. As a result serum levels of these free radicals increase, exerting a higher demand for dietary antioxidants to neutralize them.

The fact that the relation between serum levels of antioxidants and gastric cancer is more consistent than that of dietary intake levels and the disease suggests the possibility of the presence of an intrinsic factor that is altering the true relation between dietary antioxidants and the cancer. This intrinsic factor, this study argues, is the infection with H.pylori.

H.pylori infection, by increasing the production of reactive oxygen species, increases the utilization of dietary antioxidants that serve in quenching the free radicals, thus decreasing their serum levels and confounding their protective effect against gastric cancer. The purpose of this pilot study is to investigate the possibility that H.pylori infection alters the bioavailability of the dietary antioxidants: vitamin C, and vitamin E. This project will be done in preparation for an etiologic study of dietary antioxidants and gastric cancer.

Eligibility Criteria:
Inclusion Criteria:

* Adult , age 18-45

Exclusion Criteria:

1. Smoking
2. Body mass index below 18 or above 25.
3. Previous treatment for H.pylori infection
4. Partial or total gastrectomy
5. History of gastritis
6. Currently taking antioxidants supplementation
7. Training in an athletic team.
8. Drinking more than 3 servings of alcohol/day
Liver Fibrosis Assessment With ShearWave Elastography

Chronic liver disease/fibrosis can be the result of various causes, and the result is that the liver tissue becomes stiff. ShearWave™ elastography, available on the Aixplorer® ultrasound system, is a method that can be used to measure the stiffness of organs in the body, for example the liver.

This study will evaluate how this technology performs as a non-invasive test to stage liver fibrosis in patients with chronic liver disease.

The measurements of liver stiffness made by the Aixplorer® will be compared to (where available) :

* blood markers
* biopsy results
* other stiffness measurement exams (FibroScan, ARFI, ElastPQ...)

The influence of other (confounding) factors on the reliability of SWE measurements will be analyzed.

Eligibility Criteria:
Inclusion Criteria:

* Patients meeting a single condition below:

  * Chronic hepatitis B, defined by serology HBsAg positive and the presence of DNA / RNA in the serum, or
  * Chronic hepatitis C, defined by serology anti-HCV positive and the presence of DNA / RNA in the serum, or
  * non-alcoholic fatty-liver disease
* And meeting all of the conditions below:

  * liver biopsy for histological evaluation of liver fibrosis
  * Length of liver biopsy ≥ 15 mm paraffin sections (except if cirrhosis)
  * Age of majority in their country
  * Obtaining the signature of consent for participation in the data collection, in addition to the routine consent form routinely used at the sites.

Exclusion Criteria:

* Cause of chronic liver disease other than viral (alcohol, hemochromatosis, autoimmune hepatitis, biliary tract disease intrahepatic...) and other than non-alcoholic fatty-liver disease
* History of antiviral therapy for 6 months or less of current antiviral therapy
* Any systemic, viral hepatitis and HIV co-infection
* Pregnant woman
* Failure to obtain consent
* Length of all liver biopsy specimens below 15mm
A Real-world Study to Evaluate the Safety and Immunogenicity of a Third-dose Booster After Two Doses of an Inactivated COVID-19 Vaccine

This project is a prospective observational real-world study, recruiting and screening subjects who have completed 2 doses of the COVID-19 vaccine for more than 6 months and receive the third dose of the vaccine voluntarily into the clinical cohort of this study. Subjects received a third dose of the COVID-19 vaccine will be enrolled in the study and followed up for 1 year at baseline (day 0) before vaccine injection, 28 days after injection, 90 days, 270 days after injection. On the 365th day, blood samples were collected for the detection of anti-SARS-CoV-2 antibodies and other related indicators to evaluate the immune protection effect.


Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years old, gender is not limited;
* Subjects who completed the second dose of COVID-19 inactivated vaccine for more than 6 months and received the third dose of the same vaccine

Exclusion Criteria:

* allergic to the active ingredients of the SARS-CoV-2 vaccine, any of the inactive ingredients, the substances used in the production process, or those who have had allergies during previous vaccination of similar vaccines;
* those who have had severe allergic reactions to vaccines in the past (such as acute allergic reactions, angioedema, respiratory Difficulties, urticaria, angioedema or abdominal pain);
* Receiving other research drugs within 3 months ;participating in other research vaccines Or subjects in clinical trials of research drugs;
* other conditions that the investigator judges are not suitable for this clinical trial;
Telehealth-Clinical Advocacy Project

The purpose of this study is to develop a clinical telehealth intervention and test the feasibility of integrating telehealth within a police opioid county diversion program.

Participants in a police opioid diversion program will receive information about the research opportunity; those interested will be administered informed consent and randomized to either the (1) diversion program treatment as usual condition or (2) the enhanced condition, receiving the telehealth video call intervention with motivational interviewing and substance use treatment appointment reminders during the 12-week intervention. The study design has been modified to provide the enhanced condition with coaching and the T-CAP app to all individuals consented to the study beginning January 1, 2023.

Eligibility Criteria:
Inclusion Criteria:

Individuals interested in joining the study will be

* Enrolled in the A Way Out Opioid Diversion Program (ODP),
* At least 18 years of age,
* Able to speak and understand English,
* Have a history of opioid, alcohol, or other substance use within last 12 months,
* Be willing to provide the research team with access to treatment records,
* Have access to a phone, tablet or computer for the informed consent activity, and
* Have a mailing address to receive a study phone issued to consented participants

Exclusion Criteria:

Individuals not eligible for the study are

* Not currently enrolled in the A Way Out Opioid Diversion Program on the day of consent,
* Under the age of 18 on the day of consent,
* Unable to speak and understand English,
* Have a history of past opioid, alcohol, or other substance use longer than 12 months ago with no use of opioids in the last 12 months,
* Unwilling to authorize the research team to access treatment records,
* Without access to a phone, tablet or computer to complete the informed consent activity,
* Without a mailing address
Adequacy Assessment of Bronchoscopic Biopsy Samples Using a Novel Instrument

The goal of this study is to learn whether the Ruby Robotics system enables pathologists to determine whether a bronchoscopic biopsy sample is adequate for diagnosis. The main question it aims to answer is:

- Are pathologists' evaluations of Ruby digital images concordant with their evaluations of manually created rapid on-site evaluation slides?


Eligibility Criteria:
Inclusion Criteria:

* The subject will undergo a planned, non-emergent transbronchial lung and/or thoracic lymph node biopsy.

Exclusion Criteria:

-
Crave Crush Neuroimaging Study

The purpose of the research is to test whether a gymnemic acids (GA) lozenge will reduce reward region response to intake of high-sugar food and ad lib candy intake and whether the GA lozenge reduced reward region response to anticipated intake of high-sugar food and high-sugar food pictures relative to a placebo lozenge.

Test the hypothesis that an acute dose of Crave Crush will produce greater reductions in reward region response to a taste of a high-sugar/high-fat beverage and anticipated receipt of this beverage than a placebo dose.

Test the hypothesis that a dose of Crave Crush will result in reduced ad lib candy intake while the participants complete a survey after the fMRI scan. Participants will receive a second dose of Crave Crush or placebo. They will then be placed in a room to complete a few surveys. A bowl of candy will be placed on the table. Participants will be told that the candy is left over from their assessment and that they are free to have as much as they like, because the candy must be discarded after each participant.

Eligibility Criteria:
Inclusion Criteria:

* Between 18 and 50 years old
* report having a sweet tooth
* report desire to lose weight
* Body Mass Index between 18 and 40

Exclusion Criteria:

* major psychiatric disorders
* serious health problems (e.g., diabetes)
* habitual use of psychoactive drugs or medications
* contraindications for MRI scanning (e.g., ferromagnetic braces)
* gluten or lactose intolerance
* a vegan diet.
A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

The purpose of this study is to assess the safety, tolerability, drug levels, and relative bioavailability of alternate formulations of BMS-986460 in healthy adult male participants.


Eligibility Criteria:
Inclusion Criteria

* Participants must be healthy as determined by no clinically significant deviation from normal in medical history, physical examination, vital signs, 12-lead ECGs, echocardiogram or clinical laboratory assessments, as determined by the investigator.
* Participants must have a Body mass index (BMI) between 18.0 and 35.0 kilograms/meter square (kg/m2), inclusive.
* Male participants who are sexually active with individuals of childbearing potential (IOCBP) must agree to follow instructions for methods of contraception.

Exclusion Criteria:

* Participants with prior exposure to BMS-986460 or with a prior history of heart failure, ischemic heart diseases, clinically significant cardiac arrythmias, or long QT syndrome are excluded.
* Participants with left ventricular ejection fraction (≤ 50%) at screening are excluded.
* Participants with history of anaphylactic reactions are excluded.
* Participants with current or recent (within 3 months of intervention administration) gastrointestinal disease that, in the opinion of the investigator, could affect the absorption of study intervention are excluded.
* Participants with history of Gilbert's syndrome are excluded.
* Other protocol-defined Inclusion/Exclusion criteria apply.
Saphenous Nerve Block After Tibial Plateau ORIF

Fractures of the tibial plateau, while very painful, typically do not receive nerve blocks. This is because of a concern that the numbness from a nerve block would "mask" the typically painful symptoms of compartment syndrome, a condition that can lead to a permanent loss of function of the injured limb. Our study aims to evaluate the effectiveness of saphenous nerve block for pain management after surgical repair of a tibial plateau fracture. Based on cadaver studies and our clinical experience, we suspect that the saphenous nerve contributes to pain sensations of the tibial plateau and will not mask the pain from a compartment syndrome. In summary, while saphenous nerve block represents a safe option after tibial plateau open reduction internal fixation (ORIF), we aim to evaluate its effectiveness in this patient population.


Eligibility Criteria:
Inclusion Criteria:

* Tibial plateau fracture presenting for ORIF
* Age greater than or equal to 18 years

Exclusion Criteria:

* Other concomitant life-threatening injuries
* History of chronic pain prior to tibial plateau ORIF
* Age \<18 years old
* Pregnancy
* Any condition impairing patient's ability to consent to participation in study
* Existing condition contraindicating a nerve block
* Non-English Speaking
Day Case Inguinal Hernia Repair in Children. Is Laparoscopic Approach Justified?

We compare laparoscopic and classic open operation for inguinal hernia in children. Attention is focused on the recovery, surgical result and the duration of the operation and hospital stay.

Background and objective : In adults the advantages laparoscopic inguinal hernia are less pain, shorter recovery, shorter sick leave and better cosmetic result. It is not known whether laparoscopic hernia repair produces similar results in children.The objective is to compare the duration of recovery, postoperative pain and long-term surgical results between day case laparoscopic and open inguinal hernia repair in children.

Key inclusion criteria: Children included in the study must be aged four months to sixteen years of age and not have undergone any previous surgery. Of male patients those with completely descended testes are accepted.

Study type: The study is randomized, single-blinded prospective comparison between laparoscopic and open day case inguinal hernia repair in children.

Target sample size: For the assumption that there is a difference of one day in time to restore normal activities after laparoscopic and open hernia repair, target sample size of 100 patients in the laparoscopic and 100 in open repair arm should reach 90% power with p \< 0.05.

Recruitment status : From 10/ 2002 to 1/2007 89 patients (laparoscopic repair LH 47, open repair OH 42) are recruited. Primary outcome: The time to restore normal activity after surgery . Secondary Outcomes : The degree of postoperative pain, the duration of the operation, sick leave of parents, surgical result 6 months and 2 years after the repair.

Eligibility Criteria:
Inclusion Criteria:

* unilateral inguinal hernia
* age age \> 4 months, \<16 years
* fully descended testes
* study consent signed

Exclusion Criteria:

* previous abdominal or inguinal surgery
* testes not fully descended
* not healthy enough for day surgery
* age \< 4months or \>16 years
* study consent not signed